Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use
Covalent Modifiers
APRIL 14, 2023
Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, Atsushi Hirano, Hideki Kazuno, Satoshi Yamashita, Kosuke Egami, Yoshihiro Shibata, Ikuo Yamamiya, Fumiaki Yamashita, Yasuo Kodama, Kaoru Funabashi, Hiromi Kazuno, Toshiharu Komori, Satoshi Suzuki, Hiroshi Sootome, Hiroshi Hirai, and Takeshi Sagara ACS Medicinal Chemistry Letters 2023 14 (4), 396-404 DOI: 10.1021/acsmedchemlett.3c00006 Deregulating fibroblast growth factor receptor (FGFR) signaling is a promising strategy for cancer therapy.
Let's personalize your content